drugset
drugset / Trial / NCT05059626

Endometriosis and Microvascular Dysfunction; Simvastatin and Duavee

NCT05059626 ↗

Phase 4 Recruiting 28 enrolled Penn State University The John B. Pierce Laboratory · collab
RandomizedParallel-groupSingle-blindBasic science

Summary

Purpose: To determine the effects of SERM and simvastatin interventions on endothelial dysfunction in women with endometriosis. Hypothesis: Treatment with the SERM (bazedoxifene + conjugated estrogen) or with simvastatin will decrease systemic inflammation and improve specific measures of cardiovascular function including endothelium-dependent vasodilation.

Timeline

Start
2023-12-01
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bazedoxifene Other / unclassified 20 mg —
Subject Simvastatin Small molecule 10 mg —
Subject conjugated estrogens Other / unclassified 0.45 mg —

Indications

endometriosis